Page 24 - Eceptor News Today

At this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 Oct) experts will discuss if lasting remission from diabetes is feasible in the real-world setting.

Study from JAMA reveals that users of GLP-1 agonists, recent drugs for weight management, show a heightened risk of gastrointestinal complications like intestinal obstruction, gastroparesis, and pancreatitis. Though these effects are rare, those considering these drugs for weight loss should weigh the benefits against potential risks, especially if not using them for diabetes.

Researchers investigated endotype-phenotype associations in atopic dermatitis (AD) beyond its general clinical severity.

Researchers examined the antigenicity of the emerging SARS-CoV-2 subvariant BA.2.86, finding that it is not resistant to neutralizing antibodies from previously infected or vaccinated individuals, although it does show increased binding affinity to the ACE-2 receptor. The study highlights the subvariant's sensitivity and resistance to different classes of monoclonal antibodies, offering insights for future treatment and vaccine development.

Researchers performed longitudinal studies in rats to measure the sensitivity of early established versus compulsive polydipsic alcohol (or water) drinking in response to bilateral infusion of α-flupentixol, anterior dorsolateral striatum (aDLS)-dopamine (DA) receptor antagonist.

The effectiveness of virus-like particle (VLP)-based vaccines targeting epitopes in the low-density lipoprotein (LDL) receptor.

Researchers at Stanford University School of Medicine, Yale University School of Medicine, and the Hospital for Special Surgery Research Institute have uncovered new details about how the immune system prevents the production of antibodies that can recognize and damage the body's own, healthy tissues.

A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to human epidermal growth factor receptor 2 (HER2)-targeted treatment in HER2-positive metastatic breast cancer patients, according to new research published in the September issue of The Journal of Nuclear Medicine.

Researchers from the University of Texas Southwestern have developed an aerosolized, mutated form of ACE2 that effectively neutralizes various SARS-CoV-2 variants in both cell cultures and mice. The study suggests that this modified ACE2 has promising preventive and therapeutic potential against COVID-19, especially with its easy aerosolized administration.

Study highlights the ability of the Vaxzevria vaccine in inducing robust mucosal antibody responses, especially in COVID-19-recovered individuals, showcasing a notable defense against various SARS-CoV-2 variants. However, it emphasizes the need for booster doses to enhance anti-SARS-CoV-2 mucosal immunity, especially in infection-naïve individuals, to broaden protection against emerging viral variants.